Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women
- PMID: 19448391
- PMCID: PMC2684987
- DOI: 10.1007/BF03325227
Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women
Abstract
Aims: To characterize the relationship between advanced glycation end products (AGEs) and circulating receptors for AGEs (RAGE) with cardiovascular disease mortality.
Methods: The relationships between serum AGEs, total RAGE (sRAGE), and endogenous secretory RAGE (esRAGE), and mortality were characterized in 559 community-dwelling women, double dagger 65 years, in Baltimore, Maryland.
Results: During 4.5 years of follow-up, 123 (22%) women died, of whom 54 died with cardiovascular disease. The measure of serum AGEs was carboxymethyl-lysine (CML), a dominant AGE. Serum CML predicted cardiovascular disease mortality (Hazards Ratio [HR] for highest vs lower three quartiles, 1.94, 95% Confidence Interval [CI] 1.08-3.48, p=0.026), after adjusting for age, race, body mass index, and renal insufficiency. Serum sRAGE (ng/mL) and esRAGE (ng/mL) predicted cardiovascular disease mortality (HR per 1 Standard Deviation [SD] 1.27, 95% CI 0.98-1.65, p=0.07; HR 1.28, 95% CI 1.02-1.63, p=0.03), after adjusting for the same covariates. Among non-diabetic women, serum CML, sRAGE, and esRAGE, respectively, predicted cardiovascular disease mortality (HR for highest vs lower three quartiles, 2.29, 95% CI 1.21-4.34, p=0.01; HR per 1 SD, 1.24, 95% CI 0.92-1.65, p=0.16; HR per 1 SD 1.45, 95% CI 1.08-1.93, p=0.01), after adjusting for the same covariates.
Conclusions: High circulating AGEs and RAGE predict cardiovascular disease mortality among older community-dwelling women. AGEs are a potential target for interventions, as serum AGEs can be lowered by change in dietary pattern and pharmacological treatment.
Figures


Similar articles
-
Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women.Am J Kidney Dis. 2009 Jan;53(1):51-8. doi: 10.1053/j.ajkd.2008.06.018. Epub 2008 Sep 11. Am J Kidney Dis. 2009. PMID: 18789567 Free PMC article.
-
Elevated serum advanced glycation end products and their circulating receptors are associated with anaemia in older community-dwelling women.Age Ageing. 2009 May;38(3):283-9. doi: 10.1093/ageing/afp011. Epub 2009 Feb 28. Age Ageing. 2009. PMID: 19252206 Free PMC article.
-
Modulation of soluble receptor for advanced glycation end products isoforms and advanced glycation end products in long-living individuals.Biomark Med. 2021 Aug;15(11):785-796. doi: 10.2217/bmm-2020-0856. Epub 2021 Jul 8. Biomark Med. 2021. PMID: 34236256
-
Therapeutic Interventions for Advanced Glycation-End Products and its Receptor- Mediated Cardiovascular Disease.Curr Pharm Des. 2017;23(6):937-943. doi: 10.2174/1381612822666161006143032. Curr Pharm Des. 2017. PMID: 27719648 Review.
-
Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality.Int J Angiol. 2014 Mar;23(1):11-6. doi: 10.1055/s-0033-1363423. Int J Angiol. 2014. PMID: 24627612 Free PMC article. Review.
Cited by
-
Proteomics in aging research: A roadmap to clinical, translational research.Aging Cell. 2021 Apr;20(4):e13325. doi: 10.1111/acel.13325. Epub 2021 Mar 17. Aging Cell. 2021. PMID: 33730416 Free PMC article. Review.
-
Temporal reliability of serum soluble and endogenous secretory receptors for advanced glycation end-products (sRAGE and esRAGE) in healthy women.Cancer Causes Control. 2018 Oct;29(10):901-905. doi: 10.1007/s10552-018-1066-4. Epub 2018 Aug 11. Cancer Causes Control. 2018. PMID: 30099629 Free PMC article.
-
Dietary intake of advanced glycation end products did not affect endothelial function and inflammation in healthy adults in a randomized controlled trial.J Nutr. 2014 Jul;144(7):1037-42. doi: 10.3945/jn.113.189480. Epub 2014 Apr 17. J Nutr. 2014. PMID: 24744309 Free PMC article. Clinical Trial.
-
Serum carboxymethyl-lysine, disability, and frailty in older persons: the Cardiovascular Health Study.J Gerontol A Biol Sci Med Sci. 2014 Jun;69(6):710-6. doi: 10.1093/gerona/glt155. Epub 2013 Oct 14. J Gerontol A Biol Sci Med Sci. 2014. PMID: 24127427 Free PMC article.
-
Dietary advanced glycation end-products elicit toxicological effects by disrupting gut microbiome and immune homeostasis.J Immunotoxicol. 2021 Jul 24;18(1):93-104. doi: 10.1080/1547691X.2021.1959677. J Immunotoxicol. 2021. PMID: 34436982 Free PMC article. Review.
References
-
- Basta G, Schmidt AM, de Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res. 2004;63:582–592. - PubMed
-
- Vlassara H, Striker G. Glycotoxins in the diet promote diabetes and diabetic complications. Curr Diabetes Rep. 2007;7:235–241. - PubMed
-
- Kilhovd BK, Juutilainen A, Lehto S, et al. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia. 2002;50:1409–1417. - PubMed
-
- Bohlender JM, Franke S, Stein G, Wolf G. Advanced glycation end products and the kidney. Am J Renal Physiol. 2005;289:F645–F659. - PubMed
-
- Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes. 1994;43:676–683. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical